Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, in an all-cash deal valued at $3.05 billion. The move signals a major expansion of J&J’s oncology portfolio, bringing a revolutionary “cell-killing” platform into its fold to target hard-to-treat solid tumors.
A New Frontier: The RIPTAC™ Platform
At the heart of the acquisition is Halda’s proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC™) platform. Unlike traditional therapies that merely inhibit protein function, RIPTAC™ molecules are designed to bring two proteins together within a cancer cell to trigger a mechanism that leads to the cell’s destruction.
The acquisition’s lead asset, HLD-0915, is a once-daily oral therapy currently in clinical stages for the treatment of prostate cancer. Early data suggest HLD-0915 has the potential to overcome common resistance pathways that often render current treatments ineffective, offering a new lifeline for patients with advanced disease.
Read More: Johnson & Johnson to Acquire Halda Therapeutics for $3.05 Billion, Bolstering Oncology Pipeline
Expanding the Pipeline
Beyond prostate cancer, the deal provides Johnson & Johnson with a pipeline of early-stage candidates targeting breast, lung, and other solid tumors. J&J leadership believes the RIPTAC™ technology could eventually be applied to areas beyond oncology, potentially revolutionizing how oral targeted therapies are developed for a variety of complex diseases.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Financial Outlook
The $3.05 billion transaction will be accounted for as a business combination. Johnson & Johnson expects the acquisition to result in a dilution of adjusted earnings per share (EPS) by approximately $0.20, split equally between 2025 and 2026. This dilution accounts for non-recurring charges related to employee equity awards, integration, and financing costs.
J&J has a long-standing history in the prostate cancer space, and this acquisition reinforces its position as a dominant player in the field. The company is expected to provide further commentary on its 2026 financial guidance during its fourth-quarter earnings call scheduled for January 21, 2026.
